Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 100

Sort by

Sort Order Select

Journal Articles

Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Mark A Currier, Allen Reha, Brian Hutzen, Pin-Yi Wang, Chun-yu Chen, Andrea Glaspell, Siddhi Nath Paudel, Akila S Venkataramany, Debashree Das, Danielle Hanlon, Allan A. Kaspar, Samit Varma, Brian K. Kaspar, Jacob G. Scott, Pablo Morales, Peter Ralph, Tonny Johnson, Tania L. Weiss, Timothy P Cripe

Blood (2024) 144 (Supplement 1): 1056.

https://doi.org/10.1182/blood-2024-198463

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu, Weiwei Sui, Rui Lyu, Chenxing DU, Shuaishuai Zhang, Tengteng Yu, Jingyu Xu, Wenqiang Yan, Yuting Yan, Wei Liu, Yi Wang, Qi Wang, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3386.

https://doi.org/10.1182/blood-2024-200117

Published: 2024

Journal Articles

Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study

Wei Liu, Changming Dong, Yi Wang, Ting Xie, Shunjin Zhang, Xiaoxia Wang, Jinghua Wu, Xiao Liu, Dehui Zou, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2024-204594

Published: 2024

Journal Articles

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Poy Theprungsirikul, Rong Wang, Man-Yee Merl, Shi-Yi Wang, Natalia Neparidze

Blood (2024) 144 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2024-201603

Published: 2024

Journal Articles

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Ting Xie, Wei Liu, Wenyang Huang, Huimin Liu, Weiwei Sui, Yi Wang, Wenjie Xiong, Yan Xu, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2024-204363

Published: 2024

Journal Articles

TRA/D Rearrangements As a New Potential Alternative Prognostic Biomarker in Pediatric B-Cell Acute Lymphoblastic Leukemia

Jiajia Zheng, Xinni Bian, Jun Lu, Peifang Xiao, Hailong He, Yi Wang, Jie Li, Junjie Fan, Yanhua Yao, Jing Ling, Yiting Wang, Nan Chen, Xingping Lang, Jingjing Feng, Xiaojun Chen, Huafei Chen, Sheng Xiao, Sheng Xiao, Shaoyan Hu

Blood (2024) 144 (Supplement 1): 5931.

https://doi.org/10.1182/blood-2024-212299

Published: 2024

Journal Articles

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Yunfei Chen, Ting Sun, Da Gao, Wei Wang, ZePing Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang

Blood (2024) 144 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2024-202716

Published: 2024

Journal Articles

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2024-204525

Published: 2024

Journal Articles

A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study

Shiwei Hu, Xiudi Yang, Dijiong Wu, Yi Wang, Xiaoqiong Zhu, Weiying Feng, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2024-203703

Published: 2024

Journal Articles

A Phase 3, Prospective, Open-Label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease

Cecilia Marquez-Gomez, Maria Waliullah, Yi Wang, Ali G Mokdad, Jingmei Zhang

Blood (2024) 144 (Supplement 1): 5496.

https://doi.org/10.1182/blood-2024-194267

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Sarah Gooding, Chen-Yi Wang, Warren Baker, Edmund Watson, Simon Davis, Roman Fischer, Oliver McCallion, Joanna Hester, Fadi Issa, Srinivasa Rao, Nick Athanasou, Anjan Thakurta, Karthik Ramasamy, Chad C. Bjorklund, Michael Amatangelo, Anita K. Gandhi, Adam P Cribbs, Alessandro Lagana, Udo Oppermann

Blood (2024) 144 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2024-205264

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Platelet dysfunction reversal with cold-stored vs room temperature–stored platelet transfusions

Valery J. Kogler, Jeffrey A. Miles, Tahsin Özpolat, S. Lawrence Bailey, Daire A. Byrne, Morgan Bawcom-Randall, Yi Wang, Hannah J. Larsen, Franklin Reed, Xiaoyun Fu, Moritz Stolla

Blood (2024) 143 (20): 2073–2088.

https://doi.org/10.1182/blood.2023022593

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase I Study of Venetoclax Combined with Homoharringtonine, Cytarabine, and G-CSF for the Treatment of Pediatric De Novo Acute Myeloid Leukemia

Shengqin Cheng, Li Gao, Yi Wang, Peifang Xiao, Hailong He, Jun Lu, Jie Li, Yixin Hu, Liyan Fan, Raul C. Ribeiro, Cheng Cheng, Shaoyan Hu

Blood (2023) 142 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2023-188040

Published: 2023

Journal Articles

Bioactive Lipid Mediators Predict Platelet Function in Transfusion Recipients: A Phase 1 Randomized Clinical Trial in Healthy Humans

Valery J Kogler, Jeffrey Miles, Hasan Tahsin Ozpolat, Shawn Bailey, Daire Byrne, Morgan Bawcom-Randall, Yi Wang, Hannah Larsen, Franklin Reed, Xiaoyun Fu, Moritz Stolla

Blood (2023) 142 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2023-180307

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Blood (2023) 142 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2023-180736

Published: 2023

Journal Articles

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

Blood (2023) 142 (Supplement 1): 729.

https://doi.org/10.1182/blood-2023-189253

Published: 2023

NARROW

Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Harnessing Ctdna to Predict Therapeutic Success in DLBCL: Insights from a Multicenter Prospective Study

Real-World Treatment Patterns and Outcomes of Chimeric Antigen Receptor T-Cell (CART) and Bispecific T-Cell Engager (BiTE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) at the Yale Cancer Center Network (YCCN)

Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

TRA/D Rearrangements As a New Potential Alternative Prognostic Biomarker in Pediatric B-Cell Acute Lymphoblastic Leukemia

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study

A Phase 3, Prospective, Open-Label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Development of a Spatial Multiomics Platform to Integrate Genomic, Transcriptomic and Proteomic Features for Translational Research in Multiple Myeloma

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Platelet dysfunction reversal with cold-stored vs room temperature–stored platelet transfusions

A Phase I Study of Venetoclax Combined with Homoharringtonine, Cytarabine, and G-CSF for the Treatment of Pediatric De Novo Acute Myeloid Leukemia

Bioactive Lipid Mediators Predict Platelet Function in Transfusion Recipients: A Phase 1 Randomized Clinical Trial in Healthy Humans

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Outcomes of Children and Adolescents with Acute Myeloid Leukemia Given a Low-Versus Standard-Dose Chemotherapy Regimen for Remission Induction (CALSIII-AML18): A Multicenter, Phase 3, Randomized, Noninferiority Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only